Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06904287 · ClinicalTrials.gov registry record · Phase 3
Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines
A Phase 3 study of Migraine, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06904287: Recruiting Phase 3 study of Migraine, sponsored by Wake Forest University Health Sciences.
NCT06904287 is a Phase 3 study of Migraine that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 100 participants, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06904287, a Phase 3 study of Migraine, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to find out if using magnesium in addition to prochlorperazine will help reduce your migraine pain.
Primary Outcome
Change in pain score 30 minutes after initiation of infusion. Pain score is measured on a 0-11 point pain intensity numerical rating scale where 0=no pain and 10=worst possible pain.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Magnesium
Study Locations (1)
Illinois
- Advocate Christ Medical Center Emergency Department - Oak Lawn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-12-16 |
| Est. Completion | 2027-06 |
| Phase | Phase 3 |
What NCT06904287 shows while recruiting
NCT06904287 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06904287 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06904287 about?
NCT06904287 is a clinical study titled "Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines". The purpose of this research study is to find out if using magnesium in addition to prochlorperazine will help reduce your migraine pain.
What is the current status of trial NCT06904287?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2025-12-16. Estimated completion is 2027-06.
What conditions does trial NCT06904287 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT06904287?
The interventions under investigation include: Placebo (DRUG), Magnesium (DRUG).
Who is sponsoring clinical trial NCT06904287?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06904287 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06904287's enrollment target sits among peer trials
100 58th of 102 higher than 42 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
RECRUITING · Phase 3
-
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
RECRUITING · Phase 3
-
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
RECRUITING · Phase 3
-
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
RECRUITING · Phase 3
-
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI